• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Erasca, Inc. - Common Stock (NQ:ERAS)

9.620 +0.060 (+0.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Erasca, Inc. - Common Stock

News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
From FN Media Group LLC
Via GlobeNewswire
News headline image
Erasca Reports First Quarter 2024 Business Updates and Financial Results
May 08, 2024
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces $45 Million Oversubscribed Private Placement Financing
March 27, 2024
Funding from new and existing investors extends anticipated cash runway into H2 2026 
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
March 27, 2024
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
February 14, 2024
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
December 11, 2023
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
November 28, 2023
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
November 09, 2023
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at Upcoming Investor Conferences in November
November 08, 2023
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at the Cantor Global Healthcare Conference
September 19, 2023
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Reports Second Quarter 2023 Financial Results and Business Updates
August 10, 2023
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Reports First Quarter 2023 Financial Results and Business Updates
May 15, 2023
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates
March 23, 2023
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors
December 20, 2022
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
December 13, 2022
ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and systemic activity 
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
December 09, 2022
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces Pricing of Underwritten Offering of Common Stock
December 09, 2022
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
November 30, 2022
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca to Present at Upcoming Investor Conferences
November 22, 2022
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Reports Third Quarter 2022 Financial Results and Business Updates
November 09, 2022
From Erasca, Inc.
Via GlobeNewswire
News headline image
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination
October 20, 2022
From Erasca, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap